Hsk42360-na

Other Medications

1 Clinical Trials

Description

HSK42360-Na is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for solid tumors, specifically those with a BRAF V600 mutation. The trials are in the early phase (Phase 1), focusing on determining the safe dosage and how the drug is processed by the body (pharmacokinetics) and its effects on the body (pharmacodynamics). It is taken orally. This drug is not yet approved for use in colorectal cancer or any other condition.

Mechanism of Action

HSK42360-Na is being investigated for its potential activity against tumors that have a specific genetic change called a BRAF V600 mutation. The exact way HSK42360-Na works is still being studied, but it is designed to target processes within cancer cells. The specific molecular target is being characterized in clinical trials.

Side Effects

Because HSK42360-Na is in Phase 1 clinical trials The full range of potential side effects is still being evaluated. Safety and tolerability are the primary focus of these early studies. Information about common or specific side effects is not yet available from these trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07561554 Phase 1
Recruiting
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
China

Quick Info

CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.